Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 11/20 | 0.56 |
| ▸ | PPARG | P37231 | 3/20 | 0.51 |
| ▸ | PPARD | Q03181 | 2/20 | 0.51 |
| ▸ | PPARA | Q07869 | 2/20 | 0.51 |
| ▸ | BCL2 | P10415 | 3/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1609166 | 0.88 | MCL1 (0.63) | MCL1PPARGPPARDPPARABCL2 | |
| SCHEMBL1607765 | 0.88 | HDAC1 (0.51) | MCL1PPARGPPARDPPARA | |
| SCHEMBL1609317 | 0.88 | MRGPRX4 (0.53) | MCL1PPARGPPARDPPARA | |
| SCHEMBL1608656 | 0.86 | MCL1 (0.62) | MCL1BCL2NR4A2 | |
| SCHEMBL30696552 | 0.85 | MCL1 (0.55) | MCL1PPARGPPARDPPARABCL2 | |
| SCHEMBL1607754 | 0.81 | MCL1 (0.52) | MCL1PPARGPPARDPPARABCL2 | |
| SCHEMBL1608589 | 0.77 | HDAC6 (0.56) | MCL1PPARGPPARDPPARA | |
| SCHEMBL1608799 | 0.77 | MAPT (0.56) | MCL1PPARGPPARDPPARA | |
| SCHEMBL1810857 | 0.76 | MCL1 (0.60) | MCL1BCL2 | |
| SCHEMBL30696555 | 0.76 | MCL1 (0.48) | MCL1PPARGPPARDPPARABCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2265590-B1 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS LLC (US) | 2016-04-13 | — | — | EP | disclosed |
| EP-2265590-B1 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS LLC (US) | 2016-04-13 | — | — | EP | disclosed |
| US-20150320758-A1 | SELECTIVE INHIBITORS OF HISTONE DEACTYLASE | PHARMACYCLICS LLC | 2015-11-12 | — | — | US | disclosed |
| US-20150320758-A1 | SELECTIVE INHIBITORS OF HISTONE DEACTYLASE | PHARMACYCLICS LLC | 2015-11-12 | — | — | US | disclosed |
| US-20150320758-A1 | SELECTIVE INHIBITORS OF HISTONE DEACTYLASE | PHARMACYCLICS LLC | 2015-11-12 | — | — | US | disclosed |
| US-8906954-B2 | Selective inhibitors of histone deacetylase | PHARMACYCLICS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906954-B2 | Selective inhibitors of histone deacetylase | PHARMACYCLICS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906954-B2 | Selective inhibitors of histone deacetylase | PHARMACYCLICS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140004174-A1 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2014-01-02 | — | — | US | disclosed |
| US-8466193-B2 | Selective inhibitors of histone deacetylase | PHARMACYCLICS, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-8466193-B2 | Selective inhibitors of histone deacetylase | PHARMACYCLICS, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-8466193-B2 | Selective inhibitors of histone deacetylase | PHARMACYCLICS, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-20110081409-A1 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS LLC | 2011-04-07 | — | — | US | disclosed |
| US-20110081409-A1 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS LLC | 2011-04-07 | — | — | US | disclosed |
| US-20110081409-A1 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS LLC | 2011-04-07 | — | — | US | disclosed |
| EP-2265590-A2 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009129335-A2 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009129335-A2 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110081409-A1 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE | HDAC8, HDAC1, HDAC11 | MCL1 806/4885PPARG 1050/4885PPARD 1765/4885 |
| US-20150320758-A1 | SELECTIVE INHIBITORS OF HISTONE DEACTYLASE | HDAC8, HDAC1, HDAC5 | MCL1 1807/4885PPARG 1266/4885PPARD 2285/4885 |
| US-20140004174-A1 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE | HDAC8, HDAC1, HDAC11 | MCL1 806/4885PPARG 1050/4885PPARD 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.